Outlook Therapeutics, Inc.
OTLK · NASDAQ
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | 0.04 | 0.37 | 0.13 |
| FCF Yield | -69.45% | -77.73% | -21.90% | -16.38% |
| EV / EBITDA | -1.58 | -1.18 | -3.92 | -6.38 |
| Quality | ||||
| ROIC | -454.98% | -251.51% | -319.33% | -303.70% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.91 | 0.73 | 0.86 | 1.02 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | -60.08% | 24.18% | -4.46% | -70.66% |
| Safety | ||||
| Net Debt / EBITDA | -0.21 | -0.21 | 0.10 | 0.05 |
| Interest Coverage | -22.71 | -34.06 | -42.41 | -55.26 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -25,545.50 | -54,306.62 | -6,225.84 | -3,058.18 |